BBI - Brickell Biotech, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.1500
+0.0100 (+0.88%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous close1.1400
Open1.2000
Bid1.1400 x 800
Ask1.2000 x 3000
Day's range1.1443 - 1.2000
52-week range0.9900 - 6.5100
Volume202,249
Avg. volume108,450
Market cap11.126M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-3.1670
Earnings date13 May 2020
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Brickell Biotech Reports First Quarter 2020 Financial Results and Provides Corporate Update

    Brickell Biotech, Inc. (“Brickell”) (BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced financial results for the first quarter ended March 31, 2020 and provided a corporate update. “Brickell has continued to make progress during the first quarter of 2020, and we remain committed to advancing sofpironium bromide into Phase 3 clinical studies in the U.S.,” commented Robert Brown, Chief Executive Officer of Brickell. Today, Brickell announced that, based on a preliminary review of the top-line results from the 12-month Phase 3 open-label long-term safety study, in 300 subjects >9 years old with primary axillary hyperhidrosis, sofpironium bromide gel, 5% and 15% was safe and generally well tolerated, which was consistent with the earlier Phase 2 clinical trial results.

  • GlobeNewswire

    Brickell Biotech to Report First Quarter 2020 Financial Results on May 13, 2020

    Brickell Biotech, Inc. (“Brickell”) (BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that it will report its first quarter 2020 financial results after the close of the U.S. financial markets on Wednesday, May 13, 2020. Brickell’s management will host a conference call at 4:30 p.m. ET to discuss the financial results and recent corporate highlights. Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases.

  • GlobeNewswire

    Brickell Biotech Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

    BOULDER, Colo., March 18, 2020 -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated.

  • GlobeNewswire

    Brickell Biotech to Report Fourth Quarter and Full Year 2019 Financial Results on March 18, 2020

    Brickell Biotech, Inc. (“Brickell”) (BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that it will report its fourth quarter and full year 2019 financial results after the close of the U.S. financial markets on Wednesday, March 18, 2020. Brickell’s management will host a conference call at 4:30 p.m. ET to discuss the financial results and recent corporate highlights. A live webcast of the conference call can be accessed through the “Investors” tab on the Brickell Biotech website at http://www.brickellbio.com/.

  • GlobeNewswire

    Brickell Biotech Announces Late-Breaking Oral Presentation at 2020 American Academy of Dermatology Annual Meeting by its Asian Partner, Kaken Pharmaceutical, for Sofpironium Bromide

    Brickell Biotech, Inc. (“Brickell”) (BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that positive results from its development partner, Kaken Pharmaceutical Co. Ltd.’s Phase 3 pivotal study in Japan were selected for oral presentation at the Late-Breaking Research Program during the American Academy of Dermatology (AAD) Annual Meeting being held March 20-24, 2020, in Denver, CO.

  • GlobeNewswire

    Brickell Biotech Announces Publication of its U.S. Phase 2b Study Results for Sofpironium Bromide in Patients with Primary Axillary Hyperhidrosis in the Journal of the American Academy of Dermatology

    Brickell Biotech, Inc. (“Brickell”) (BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that positive results from its Phase 2b study with sofpironium bromide in patients with primary axillary hyperhidrosis were published in the peer-reviewed Journal of the American Academy of Dermatology (JAAD). The paper, entitled “Efficacy and Safety of Topical Sofpironium Bromide Gel for the Treatment of Axillary Hyperhidrosis: A Phase 2, Randomized, Controlled, Double-Blinded Trial,” is now available online (Journal Pre-proof) at (https://doi.org/10.1016/j.jaad.2020.02.016) and will be published in a future print edition of JAAD.

  • GlobeNewswire

    Brickell Biotech Announces Settlement of Dispute with Bodor Labs and Entry into Equity Funding Agreements

    Brickell Biotech, Inc. and its subsidiary (collectively, “Brickell”) (BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced Brickell, and Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor (collectively, “Bodor”), entered into a settlement agreement and an amended license agreement. This resolves the previously disclosed dispute related to the sofpironium bromide license agreement and allows the Company to continue its efforts to develop sofpironium bromide for the treatment of hyperhidrosis, a life-altering medical condition with an estimated 15 million sufferers in the United States.

  • GlobeNewswire

    Brickell Bio’s Development Partner, Kaken Pharmaceutical, Submits New Drug Application for Sofpironium Bromide in Japan for Primary Axillary Hyperhidrosis

    Brickell Biotech, Inc. (“Brickell”) (BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that its development partner, Kaken Pharmaceutical Co. Ltd. (“Kaken”) submitted a new drug application for approval of manufacturing and marketing for sofpironium bromide in Japan for primary axillary hyperhidrosis. The application for sofpironium bromide in Japan involves data from the Phase 3 study in Japan, targeting patients with primary axillary hyperhidrosis, in which positive results were obtained.

  • GlobeNewswire

    Brickell Bio Announces Third Quarter 2019 Financial Results and Provides Corporate Update

    BOULDER, Colo., Nov. 13, 2019 -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated.

  • GlobeNewswire

    Brickell Biotech Provides Update on Bodor Labs Complaint and Funding Agreement with NovaQuest

    Brickell Biotech, Inc. (“Brickell”) (NASDAQ: BBI), a clinical-stage pharmaceutical company, today announced that it has initiated an arbitration proceeding pursuant to Article 9 of the License Agreement previously entered into between Bodor Laboratories, Inc. (“Bodor”), Nicholas S. Bodor and Brickell with the American Arbitration Association (“AAA”) in Florida against Bodor and Nicholas S. Bodor. This arbitration seeks a declaratory judgment that the purported termination of the License Agreement by Bodor and Nicholas S. Bodor was invalid and unenforceable and asserts (i) a claim for breach of the License Agreement against Bodor and Nicholas S. Bodor, in his individual capacity, and (ii) a claim against Bodor and Nicholas S. Bodor for tortious interference with Brickell’s business relations.

  • GlobeNewswire

    Brickell Biotech Completes Merger with Vical

    Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company, today announced the completion of its merger with Vical Incorporated (“Vical”), following approval by Vical’s stockholders.